论文部分内容阅读
本文探讨小鼠宫颈癌单克隆抗体（ＡＴ１４－１）对带瘤动物的疗效。动物经不同途径接种不同数量的可移植性宫颈癌（Ｕ１４）细胞；然后给治疗组的动物从腹腔注入不同剂量的ＡＵ１４－１。结果表明，ＡＵ１４－１可延长带有腹水型或实体型肿瘤小鼠的存活期，且可治愈其中某些动物；但其功效受不列条件的制约：接种的肿瘤细胞数量，治疗的肿瘤类型，所用的单克隆抗体剂量，以及单克隆抗体与肿瘤细胞的结合程度。本研究提示，ＡＵ１４－１在特定条件下有可能应用于人体宫颈癌的免疫治疗。
This article discusses the mouse cervical cancer monoclonal antibody (AT14-1) on tumor-bearing animals. Animals were inoculated with different numbers of transplanted cervical cancer (U14) cells by different routes; animals in the treatment group were then injected intraperitoneally with different doses of AU14-1. The results show that AU14-1 can prolong the survival of mice with ascites or solid tumors and can cure some of these animals; however, their efficacy is governed by a number of conditions: the number of tumor cells inoculated, the type of tumor treated , The amount of monoclonal antibody used, and the degree of binding of the monoclonal antibody to the tumor cells. This study suggests that AU14-1 may be applied to the immunotherapy of human cervical cancer under certain conditions.